In this study, we aimed to assess the prevalence of interstitial lung abnormalities (ILAs) and investigate the rates and risk factors associated with radiologic ILA progression among patients with lung cancer following surgical resection. Patients who underwent surgical resection for lung cancer at our institution from January 2015 to December 2020 were retrospectively evaluated and grouped according to their ILA status as having no ILAs, equivocal ILAs, or ILAs. Progression was determined by simultaneously reviewing the baseline and corresponding follow-up computed tomography (CT) scans. Among 346 patients (median age: 67 (interquartile range: 60–74) years, 204 (59.0%) men), 22 (6.4%) had equivocal ILAs, and 33 (9.5%) had ILAs detected upon baseline CT. Notably, six patients (6/291; 2.1%) without ILAs upon baseline CT later developed ILAs, and 50% (11/22) of those with equivocal ILAs exhibited progression. Furthermore, 75.8% (25/33) of patients with ILAs upon baseline CT exhibited ILA progression (76.9% and 71.4% with fibrotic and non-fibrotic ILAs, respectively). Multivariate analysis revealed that ILA status was a significant risk factor for ILA progression. ILAs and equivocal ILAs were associated with radiologic ILA progression after surgical resection in patients with lung cancer. Hence, early ILA detection can significantly affect clinical outcomes.

This research evaluated the diagnostic accuracy and complication rate of computed tomography (CT)-guided percutaneous transthoracic lung biopsy (PTNB) in patients 80 years and older. The study sought to identify risk factors for diagnostic failures or complications of PTNBs. We examined 247 CT-guided PTNBs performed from January 2017 through December 2020, noting patient demographics, lesion or procedure types, pathology reports, and other procedure-related complications. Study groups were divided into two: one with patients aged 80 years and older (Group 1) and the other with patients aged 60 to 80 years (Group 2). The research first determined each groups’ diagnostic accuracy, sensitivity, specificity, diagnostic failure rate, and complication rate and then evaluated the risk factors for diagnostic failures and complications. The diagnostic accuracy, sensitivity, specificity, and diagnostic failure rates were 95.6%, 94.9%, 100%, and 18.9%, respectively, in Group 1. The overall and major complication rates in Group 1 were 29.6% and 3.7%, respectively. Lesion size was the only risk factor for diagnostic failure (adjusted odds ratio [OR], 0.46; 95% confidence interval [CI], 0.24–0.90). There was no significant risk factor for complications in Group 1. CT-guided PTNBs in patients 80 years and older indicate comparable diagnostic accuracy and complication rates.

Rationale: Primary pulmonary synovial sarcoma is a rare malignant pulmonary tumor accompanied by calcifications in approximately 15% of cases. These calcifications usually have a fine, stippled appearance; coarse shapes have seldom been reported. Moreover, the presence of coarse calcifications often suggests benign tumors, which vastly differ in treatment. We present a rare case of primary pulmonary sarcoma with coarse intratumoral calcifications, the diagnosis of which was delayed because of its radiologic appearance. Patient concerns: A computed tomography (CT) scan of a 69-year-old man with right upper quadrant (RUQ) pain revealed an incidental mass at the base of the right lower lobe, the margin of which was not well described with respect to the liver, and intratumoral coarse calcification was noted. Initially, the lesion was believed to be hepatic, and magnetic resonance imaging (MRI) was performed. Based on its imaging features, the mass was thought to be a pulmonary lesion, and a preliminary diagnosis of a benign lesion, such as a hamartoma or granuloma, was made. Four months after the initial CT scan, the patient’s RUQ pain had aggravated; however, no change in the mass was observed on follow-up CT. Diagnosis: The final diagnosis was primary pulmonary sarcoma, proven by surgical biopsy. Interventions: Wedge resection of the right lower lobe was performed, and the patient received adjuvant chemotherapy. Outcomes: The patient’s RUQ pain improved, and no recurrence or metastasis has been reported to date. Lessons: This case describes a rare presentation of a primary pulmonary synovial sarcoma with coarse intratumoral calcifications and the MRI features of the lesion. Intratumoral coarse calcifications often suggest benign lesions, such as hamartomas or post-inflammatory granulomas; however, as malignant lesions cannot be completely excluded, other radiologic and clinical features should be considered carefully. Focal areas of enhancement and eccentric calcification distribution might suggest malignant lesions such as primary pulmonary synovial sarcoma. Furthermore, despite not being used routinely, MRI scans might be helpful because advanced MRI techniques, such as diffusion-weighted imaging, can help distinguish malignant lesions from benign lesions. If the clinical course of a patient suggests malignancy, a more aggressive biopsy strategy should be considered.

Background/Objectives: To evaluate changes in background parenchymal enhancement (BPE) in the contralateral breast on MRI before and after neoadjuvant chemotherapy (NAC), stratified by molecular subtype in patients with unilateral breast cancer. Methods: This study retrospectively analyzed 116 individuals diagnosed with unilateral breast cancer by biopsy, all of whom underwent breast MRI examinations before and after neoadjuvant chemotherapy. Contralateral breast BPE was graded into four levels (BPEC: 1 = minimal, 2 = mild, 3 = moderate, 4 = marked) by two readers in consensus. Histopathological features and BPE reduction were compared according to molecular subtype. Results: BPE showed a reduction across all molecular subtypes after NAC. In ER-positive cancers, BPEC shifted from 26/16/28/30% to 68/28/4/0%; in HER2-positive cancers, from 37.8/26.7/22.2/13.3% to 73.3/20.0/6.7/0%; and in triple-negative breast cancers, from 47.6/14.3/23.8/14.3% to 76.2/14.3/9.5/0%. Compared to the ER-positive cancer, the reduction in BPE over time was significantly greater in the HER2-positive cancer group (Estimate = 0.48, p = 0.0168) and TNBC (Estimate = 0.55, p = 0.0321), suggesting that the extent of BPE decrease varied by subtype. Conclusions: The extent of BPE reduction on breast MRI following NAC varies significantly across different molecular subtypes of breast cancer.